FDA ap­proves As­traZeneca’s Imfinzi be­fore and af­ter lung can­cer surgery

The FDA ap­proved As­traZeneca’s check­point in­hibitor Imfinzi for use in cer­tain lung can­cers be­fore and af­ter surgery, as the phar­ma com­pa­ny fol­lows in the foot­steps …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER